Patent classifications
C07D239/54
Non-nucleoside reverse transcriptase inhibitors
Compounds of Formula I: ##STR00001##
are HIV reverse transcriptase inhibitors, wherein R.sup.1, R.sup.2, R.sup.E, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Protoporphyrinogen oxidase inhibitor mixtures
The present invention is directed to agricultural mixtures comprising a protoporphyrinogen oxidase inhibitor compound of formula (I), ##STR00001##
(I and a C16 to C18 fatty acid methyl ester adjuvant system. The present invention is further directed to methods of increasing the activity of a protoporphyrinogen oxidase inhibitor compound of formula (I) with the mixtures of the present invention.
Protoporphyrinogen oxidase inhibitor mixtures
The present invention is directed to agricultural mixtures comprising a protoporphyrinogen oxidase inhibitor compound of formula (I), ##STR00001##
(I and a C16 to C18 fatty acid methyl ester adjuvant system. The present invention is further directed to methods of increasing the activity of a protoporphyrinogen oxidase inhibitor compound of formula (I) with the mixtures of the present invention.
Coferons and methods of making and using them
The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.
Coferons and methods of making and using them
The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.
Uracil containing compounds
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES
The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES
The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
Deoxyuridine triphosphatase inhibitors
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions. ##STR00001##
Deoxyuridine triphosphatase inhibitors
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions. ##STR00001##